Pharmacologic Treatment of Pulmonary Arterial Hypertension

Author(s): Gautam V. Ramani, Sartraj Gill

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 22 , 2013

Become EABM
Become Reviewer
Call for Editor


Pulmonary arterial hypertension (PAH) is a rare, incurable disease characterized by adverse remodeling of the pulmonary vasculature, leading to increased pulmonary arterial pressures and right ventricular failure. Contemporary pharmacotherapy targets 3 distinct molecular pathways that are abnormal in PAH: deficient production of nitric oxide and prostacyclin, and over production of endothelin. Risk assessment is critical in guiding therapeutic decision making and in disease surveillance following treatment initiation. Patients with more advanced disease are best treated with continuous infusion therapy, while those less symptomatic patients may respond to oral or inhaled therapies. Combination therapy is being increasingly utilized in patients who fail to achieve treatment goals.

Keywords: Pulmonary hypertension, pulmonary arterial hypertension, right ventricle failure, prostacyclins, endothelin receptor antagonist.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 08 May, 2013
Page: [3963 - 3973]
Pages: 11
DOI: 10.2174/1381612811319220004
Price: $65

Article Metrics

PDF: 13